Network module-based drug repositioning for pulmonary arterial hypertension

Area of Science:

• Cardiovascular research
• Pharmacology
• Bioinformatics

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition causing pulmonary vascular remodeling, leading to poor prognosis despite current treatments.
• Existing therapies for PAH have limited long-term efficacy, highlighting the urgent need for novel treatments targeting the disease's core mechanisms.
• Reversing pulmonary vascular remodeling is a key therapeutic goal for improving survival and quality of life in PAH patients.

Purpose of the Study:

• To develop a novel network module-based framework for identifying potential drug repositioning candidates for pulmonary arterial hypertension (PAH).
• To prioritize drugs whose targets are closely associated with the PAH disease module within the human protein-protein interactome.
• To provide mechanistic insights into how repurposed drugs could address the underlying pathobiology of PAH.

Main Methods:

• Integrated drug-drug interactions, chemical similarity, drug targets, and PAH disease proteins into the human interactome.
• Utilized a network module-based approach to analyze relationships between existing PAH drugs and disease proteins.
• Prioritized candidate drugs based on their proximity to the PAH disease module in the protein-protein interaction network.

Main Results:

• Identified 53 candidate drugs with potential for repurposing to treat pulmonary arterial hypertension (PAH).
• Many identified drug candidates have existing literature supporting their potential therapeutic relevance.
• The network module-based approach provided mechanistic explanations for the potential efficacy of the repurposed drugs.

Conclusions:

• Network module-based drug repositioning is a viable strategy for discovering novel therapies for PAH.
• This approach can identify drugs that may reverse pulmonary vascular remodeling by targeting underlying pathobiological mechanisms.
• The identified 53 drug candidates warrant further investigation for their therapeutic potential in PAH treatment.